67 results on '"Paulden, Mike"'
Search Results
2. Decision Makers Should Avoid the Health Years in Total (HYT) Approach: A Response to Dr Basu
3. A Framework for the Fair Pricing of Medicines
4. Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained
5. OP47 The Risk-Based Price: Incorporating Uncertainty And Risk Attitudes In Health Technology Pricing
6. Challenges of calculating cost-effectiveness thresholds
7. Direct equity weights
8. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment
9. Prediction of odds for emergency cesarean section: A secondary analysis of the CHILD term birth cohort study
10. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates
11. Life at a Premium: Considering an End-of-Life Premium in Value-Based Reimbursement
12. Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents
13. Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates
14. Economic Evaluation of Sucrose Octasulfate Dressing for the Treatment of Diabetic Foot Ulcers for Type 2 Diabetes Patients
15. Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial
16. Modifying NICE’s Approach to Equity Weighting
17. NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests
18. The risk-based price: incorporating uncertainty and risk attitudes in health technology pricing
19. Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier
20. Quality of reporting of economic evaluations in rehabilitation research: a systematic review
21. Implementing Interventions with Varying Marginal Cost-Effectiveness: An Application in Precision Medicine
22. Correction to: Calculating and Interpreting ICERs and Net Benefit
23. The health and financial impacts of a sugary drink tax across different income groups in Canada
24. Calculating and Interpreting ICERs and Net Benefit
25. Why it’s Time to Abandon the ICER
26. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
27. The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?
28. Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model
29. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer
30. Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines
31. Non‐pharmacological management of persistent headaches associated with neck pain: A clinical practice guideline from the Ontario protocol for traffic injury management (OPTIMa) collaboration
32. PP10 Quality Of Reporting Economic Evaluations In Rehabilitation Research
33. OP34 One-Way Sensitivity Analysis For Cost Effectiveness Analysis
34. Accounting for Timing when Assessing Health-Related Policies
35. Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models
36. Turning High‐Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long‐Term Care
37. Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky guest editorial
38. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
39. Incorporating equity in economic evaluations: a multi-attribute equity state approach
40. A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models
41. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable?
42. Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process
43. A probabilistic threshold analysis of metformin (Met) with enzalutamide (Enza) to determine the cost and added efficacy needed to make such a combination theray cost-effective (CE).
44. Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process
45. Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
46. Which interventions are cost-effective for the management of whiplash-associated and neck pain-associated disorders? A systematic review of the health economic literature by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
47. Determinants of Change in the Cost-effectiveness Threshold
48. Cancer Drugs Fund 2.0: A Missed Opportunity?
49. Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
50. Metformin (Met): A cost-effective adjunct therapy with enzalutamide (Enza) for metastatic castrate-resistant prostate cancer (mCRPC)?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.